Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. by Guerrouahen, Bella S et al.
DASATINIB INHIBITS THE GROWTH OF MOLECULARLY
HETEROGENEOUS MYELOID LEUKEMIAS
Bella S. Guerrouahen1,2, Muneyoshi Futami3, Christos Vaklavas1,4, Jukka Kanerva1,*,
Zakary L. Whichard3, Kenechi Nwawka1, Elisabeth G. Blanchard1, Francis Y. Lee5, Lisa J.
Robinson6, Robert Arceci7, Steven M. Kornblau8, Eric Wieder8, Yvon E. Cayre9, and Seth J.
Corey1,3,10
1Division of Pediatrics, UT-MD Anderson Cancer Center, Houston, TX,
2Université du Paris-Sud 11, Paris, France
3Division of Pediatric Hematology/Oncology and Transplantation, Children’s Memorial Hospital and
the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of
Medicine, Chicago, IL
4Department of Internal Medicine, The University of Texas Medical School at Houston
5Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey
6Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
7Department of Oncology, Division of Pediatric Hematology-Oncology, Johns Hopkins School of
Medicine, Baltimore, MD
8Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center,
Houston, TX
9Pierre and Marie Curie University and Robert Debré Hospital, Paris, France
10Department of Leukemia, MD Anderson Cancer Center, Houston, TX
Abstract
Purpose—Dasatinib is a dual Src/Abl inhibitor, recently approved for Bcr-Abl+ leukemias with
resistance or intolerance to prior therapy. Because Src kinases contribute to multiple blood cell
functions by triggering a variety of signaling pathways, we hypothesized that their molecular
targeting might lead to growth inhibition in acute myeloid leukemia (AML).
Experimental Design—We studied growth factor-dependent and independent leukemic cell lines,
including three cell lines expressing mutants of receptor tyrosine kinases (Flt3 or c-Kit) as well as
primary AML blasts for responsiveness to dasatinib.
Results—Dasatinib resulted in the inhibition of Src family kinases in all cell lines and blast cells
at ~10−9 M. It also inhibited mutant Flt3 or Kit tyrosine phosphorylation at ~10−6 M. Mo7e cells
expressing the activating mutation (codon 816) of c-Kit were most sensitive to growth inhibition
with a GI50 5×10−9 M. Primary AML blast cells exhibited growth inhibition < 10−6 M. Cell lines
which showed growth inhibition at ~10−6 M demonstrated a G1 cell cycle arrest and correlated with
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accumulation of p21 and p27 protein. Addition of rapamycin or cytotoxic agents enhanced the growth
inhibition. Dasatinib also caused the apoptosis of Mo7e cells expressing oncogenic Kit.
Conclusions—While all of the precise targets for dasatinib are not known, this multi-kinase
inhibitor causes either growth arrest or apoptosis in molecularly heterogeneous AML. Addition of
cytotoxic or targeted agents can enhance its effects.
INTRODUCTION
The treatment of acute myeloid leukemia (AML) remains challenging (1). Molecular profiling
has correlated well with its phenotypic diversity (2). Nonetheless, AML results from two
profound disturbances in hematopoiesis: a gain-of-function in proliferation and a loss-of-
function in complete differentiation (3). A mutation in a transcription factor commonly blocks
myeloid differentiation, while aberrant tyrosine kinase activity promotes excessive
proliferation and survival (4). The clinical efficacy of imatinib mesylate in chronic myeloid
leukemia (CML) has encouraged research on tyrosine kinases and their inhibitors in
hematologic malignancies (5). Receptor tyrosine kinases (RTK) mediate cytokine effects to
the intracellular signaling pathways, whereas cytoplasmic protein tyrosine kinases are activated
by cytokine receptors. Tyrosine kinase signaling cascades play a major role in both benign and
malignant hematopoietic cell signaling (6). One of the most common genetic abnormalities in
AML is a gain-of-function mutation in the receptor tyrosine kinase Flt3 (FMS-like tyrosine
kinase-3) due to internal tandem duplication (ITD). The constitutively active Flt3-ITD is
associated with inferior prognosis and is present in approximately 30% of AML (5). Point
mutations in kinase domains confer gain of function for Kit (Stem Cell Factor Receptor) and
Flt3. Thus, approximately half of adult AML cases possess aberrant RTK activity. Recent
sequencing of tyrosine kinase domains have not revealed mutations to account for the other
half (7,8). However, leukemic cell proliferative growth may be conferred by cryptic
translocations, mutations outside of the sequenced kinase domains, or aberrant activation of
accessory kinases. We and others have previously shown that activation of Flt3 leads to Src-
family kinase (SFK) Lyn activation(9),(10). Another leukemia associated gain-of-function
mutation in an RTK occurs with mutations of c-Kit, e.g., at codon 816 (11-13), and may also
be associated with a poor outcome (14,15). Lyn contributes also to Kit signaling (16,17). Lyn
activates the phosphatidylinositol 3′-kinase (PI 3′K)/Akt and Ras-ERK1/2 pathways, which
are essential for proliferation and inhibition of apoptosis (6). Inhibition of Flt3 with small-
molecule inhibitors has decreased leukemic burden in clinical trials (18) and improved survival
in mouse models of mutant Flt3 leukemias (19).
Dasatinib is a small-molecule kinase inhibitor used for the treatment of Bcr-Abl+ CML and
ALL with imatinib resistance or intolerance to previous therapy(20,21). Dasatinib inhibits Bcr-
Abl kinase activity in the low-nanomolar range and inhibits all clinically relevant imatinib-
resistant forms with the exception of the common T315I mutation. It has been shown that
targeting Src kinases with dasatinib may delay transition of CML chronic phase to blast crisis,
and may be effective in treating Ph+ B-ALL (22). Dasatinib is also being studied in adults with
solid tumors with preliminary results suggesting activity for dasatinib in gastrointestinal
stromal cell tumors, which possess an activating Kit mutation (23). Patients with mastocytosis
due to c-Kit mutations also benefit from dasatinib (24).
We sought to study the efficacy of dasatinib on the growth of leukemic cell lines expressing
gain-of-function mutations in an RTK, cytokine-driven proliferation and survival via the IL-3/
GM-CSF receptor, and factor-independency. We also studied dasatinib on primary AML
blasts. Our results indicate that dasatinib can inhibit SFK at 10−9 M, as well as leukemic cell
line growth at ~10−6 M concentrations and primary AML cell growth at < 10−6 M. Cells
expressing the D816H mutant of Kit were the most sensitive. Because growth inhibition
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occurred typically at micromolar concentrations, additional kinases or pathways are relevant.
Proteomic array suggests additional targets. Cell cycle arrest could be observed which
correlated with increased levels of p27 and p21. Combining dasatinib with other compounds
such as rapamycin or cytarabine may be advantageous.
MATERIALS AND METHODS
Reagents
Bristol-Myers (Princeton, NJ) provided the Src/Abl kinase inhibitor dasatinib, and its stock
solution was prepared by dissolving the compound in DMSO at 10 mM and stored at −20°C.
Rapamycin and etoposide (Calbiochem, San Diego, CA) were dissolved in DMSO and
cytarabine (Sigma-Aldrich, St. Louis, MO) in water. Trypan blue was purchased from Sigma-
Aldrich. The MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell
proliferation assay was purchased from America Type Culture Collection (ATCC, Manassas,
VA).
Leukemic cells
Ba/F3-Flt3ITD, engineered to express the Flt3 internal tandem duplication mutation as
described elsewhere(9), is an IL-3 independent murine pro-B cell line. MV4-11 is human acute
monocytic leukemia cell line expressing Flt3ITD, which was obtained from the ATCC. Mo7e
is a human acute megakaryoblastic leukemia cell line, dependent on either human Interleukin-3
(IL-3), Stem Cell Factor (SCF), or Granulocyte/Macrophage Colony-Stimulating Factor (GM-
CSF) for survival and proliferation A strain of Mo7e cells were engineered to express the
D816H mutation of c-Kit as described elsewhere(11). U937 and THP-1 are factor-independent
myeloid leukemia cell lines and were obtained from the ATCC and Yvon Cayre. K562 cells
were derived from a patient with CML myeloid blast crisis, which were obtained from Dr. Joya
Chandra, MD Anderson Cancer Center. MV4-11 cells were grown in Iscove’s media
supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine (GIBCO, Gaithersburg,
MD), 100 u/ml penicillin/streptomycin (GIBCO), and 5 ng/mL rhGM-CSF (Berlex, Richmond,
CA). Mo7e cell lines were grown in RPMI-1640 supplemented with 10% FCS, 2 mM L-
glutamine, 100 u/ml penicillin/streptomycin, and 5 ng/mL recombinant human SCF. Ba/F3-
Flt3ITD cells were maintained in medium containing 2 ng/ml murine IL-3 (Peprotech Inc,
Rocky Hill, NJ), under these conditions their growth is not dependent on expression of mutant
Flt3. When dasatinib and other compounds were tested, the IL-3 was washed from the Ba/F3-
Flt3ITD cells; in the absence of added growth factors, the survival and proliferation of Ba/F3-
Flt3ITD are dependent on their expression of constitutively active Flt3 mutant(9). K562,
THP-1, and U937 were grown in RPMI medium supplemented with 10% FCS, 2 mM L-
glutamine and 100 u/ml penicillin-streptomycin. Primary AML blast cells were obtained prior
to therapy from bone marrow aspirates or peripheral blood after informed consent based on an
IRB approved protocol at MD Anderson Cancer Center. These samples were classified
according to the FAB system and M3, M6 and M7 samples were excluded. A mononuclear
cell fraction was prepared following ficoll-hypaque separation and cryopreserved. Aliquots of
blast cells were rapidly thawed at 37°C, washed with RPMI, and resuspended at 600,000 cells/
ml in RPMI supplemented with 20% FCS. Cell viability ranged from 50 to 80% and represented
specimens containing at least 70% blasts.
Lyn siRNA treatment of Mo7e cells
Scrambled or siRNA to human Lyn was purchased from Dharmacon (Littleton, CO). Cell line
nucleofector kit V was purchased from Amaxa Biosystems (Gaithersburg, MD), and
nucleofection of Mo7e cells was performed according to the manufacturer’s optimized
protocol. Briefly, 2 ×106 cells per nucleofection sample were harvested after cells were freshly
split, and the cell pellet resuspended in prewarmed Nucleofector Solution V. Cell suspension
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(100 μL) was incubated with different concentration of siRNA or control (200 nM each) and
transferred into Amaxa-certified cuvettes. Nucleofection was carried out according to program
X-01. Cells were harvested after 24, 48 and 72 hours after nucleofection for analysis of protein
levels of Lyn by Western blot.
Growth Inhibition Assays
Cellular growth was analyzed by both Trypan blue exclusion and tetrazolium-based metabolic
assay. Cell lines had been split before addition of dasatinib or DMSO as control diluent (both
at 0.1% vol/vol) for indicated times. They were then collected, diluted in trypan blue dye
(Sigma) for counting with hemocytometer. Alternatively, the methylthiazoletetrazolium
(MTT) cell proliferation assay was performed according to manufacturer’s instructions. Cells
were cultured in 96 well- plates using same growth media and drug concentrations as in trypan
blue assay. At indicated time points, measurement of MTT activity was performed on a
Spectramax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA). GI50 values
were calculated using Calcusyn software (Biosoft, Ferguson, MO).
Cell cycle analysis
After cells were treated with dasatinib (or DMSO control) for 24 hours, 106 cells were collected
for each condition, washed with PBS and fixed in 70% ethanol for at least 1 hour at 4°C. Cells
were then washed twice with PBS and stained with 0.05 mg/ml propidium iodide solution for
2 hours on ice in the dark. RNase (20 ug/ml) was added before samples were read with
FACSCalibur (Becton Dickinson, San Jose, CA) with the Channel FL-2H. Histograms of cell
numbers vs. linear integrated red fluorescence were recorded at low settings and analyzed with
ModFit Software LT3.0 (Verity Software House, Topsham, ME).
Western Blotting
Approximately 5 × 106 cells per aliquot of the cell lines were incubated with varying
concentrations of dasatinib, rapamycin, and cytarabine for 60 minutes at 37°C. DMSO served
as the diluent control. Ba/F3-Flt3ITD cells were washed free of IL-3, before being incubated
with dasatinib. The other lines were incubated in similar conditions as in the cellular
proliferation assays. After the incubation, cells were washed twice in PBS and lyzed with
radioimmunoprecipitation assay (RIPA) lysis buffer supplemented with protease inhibitors
(PI-cocktail, PMSF, and EDTA) and phosphatase inhibitors (NaF, Na3VO4). Lysates (30 ug/
lane) were electrophoresed on SDS-PAGE gels. Gels were transferred onto Immobilon-P
Transfer membrane (Millipore Corp., Bedford, MA). The membranes were blocked 1 hour at
4°C with blocking buffer, PBS 0.1% Tween-20 supplemented with either 5% BSA or milk,
depending on the antibody. Immunoblotting was performed with polyclonal phospho-Src
(Tyr416) antibody (#2101, Cell Signaling, Beverly, MA) phospho-Lyn (Tyr396) rabbit
monoclonal antibody (Epitomics, Burlingame, CA), and phospho-Lyn (Tyr507) antibody (Cell
Signaling). Lyn expression was detected with a polyclonal antibody (#sc-15, Santa Cruz
Biotechnology, Santa Cruz, CA). Cbl was immunoprecipitated or blotted with polyclonal Cbl
(C-15) antibody (#sc-170 Santa Cruz Biotechnology). Flt3 was immunoprecipitated or blotted
with polyclonal Flt3 antibody (#sc-479, Santa Cruz Biotechnology) and c-Kit was
immunoprecipitated or blotted with a rabbit polyclonal antibody (Cell Signaling). Lysates from
immunoprecipitates were probed with monoclonal antibody (Clone 4G10, #05-321, Upstate,
Lake Placid, NY). CrkL was detected with a polyclonal antibody (#sc-319), and CrkL
phosphorylation (Tyr207) with a polyclonal antibody from Cell Signaling (#3181). Blotting
for cyclin-dependent kinase inhibitors was done with p27 antibody from Santa Cruz (sc-527)
or p21 antibody from BD Transduction laboratories (# 610233). After the incubation with the
primary antibody for one hour at room temperature or overnight at 4°C, the blots were incubated
with the secondary antibody for one hour, at room temperature. Apoptosis was determined by
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blotting for caspase 3 (Cell Signaling, #9665) and cleaved caspase 3 (Cell Signaling, #9664).
Immunoreactive bands were visualized by using a developing solution (Western Lightening,
Perkin Elmer LAS, NEL104, Boston). Membranes were restored using a stripping buffer
(Pierce, Rockford, IL) for 30 minutes at 37°C, reblocked and reprobed for actin (actin antibody,
#sc-1615, Santa Cruz Biotechnology) or total protein as a loading control. Densitometric
analysis was performed with NIH ImageJ software1. Sensitivity analysis on Lyn tyrosine
phosphorylation patterns was performed with Microsoft Excel™ software.
Phosphoproteome analysis
High throughput analysis of phospoprotein content was performed using the Kinex™ Antibody
microarray (Kinexus Bioinformatics Corporation, Vancouver, Canada) following treatment
with low (10−9 M) and high (10−5 M) dose dasatinib. Mo7e cells were treated 1 hour with
dasatinib or its vehicle DMSO as a control. After treatment, cells were collected and total
protein lysates were prepared according to the protocols recommended by Kinexus. Protein
lysates were then labeled and incubated on the Kinex™ Antibody microarrays on which
approximately 500 pan-specific and 300 phosphosite specific antibodies were immobilized.
Following the complete quantification of all detected spots, we extracted information of the
Percent CFC (Change from Control) reflecting a measure of change in normalized signal
intensity averages between the treated and the control samples.
Combination Studies
Dose-effect curves for the individual drugs were done for Ba/F3 FLT3 ITD cell lines. The
experiment was repeated using the drugs alone and in combination Approximately equipotent
concentrations of the individual drugs were used in the combination study to assess drug
interactions (Supplementary Table 1). The combination index (CI) provides a numerical value
for synergism or antagonism between two drugs. The data for combination index was generated
using the Calcusyn Software (Biosoft, Cambridge, UK). CI <1, CI=1, and CI >1 indicate
synergism, additive effect, and antagonism between the medicines respectively(25). No
sigmoidal dose-effect curves could be generated for rapamycin, so the median effect method
could not be used in the combination studies involving rapamycin. Instead, analysis of
potentiation versus inhibition was performed(26). Ba/F3 FLT3 ITD cells were grown at
escalating concentrations of dasatinib along with fixed concentrations of rapamycin (10−9M,
10−8M, and 10−7 M). The GI50 of dasatinib in combination with fixed concentration of
rapamycin was calculated using Calcusyn and was compared with the GI50 of dasatinib alone
on the same cell line.
Statistical Analysis
Means between 2 or 3 groups were calculated using a two-sided Student’s t-test or analysis of
variance (ANOVA) with PRISM (GraphPad Software, San Diego, CA).
RESULTS
Targeting Lyn in myeloid cell growth
Because we and others have shown that Lyn plays a role in myelopoiesis, we hypothesized
that specific targeting of Lyn by siRNA would result in decreased cell growth of AML cells.
Mo7e cells require the presence of a hematopoietic growth factor, such as IL-3, GM-CSF or
SCF, to survive and proliferate. Treatment of Mo7e cells with siRNA to Lyn resulted in
decreased Lyn protein levels, compared to scrambled control RNA or mock-nucleofected cells,
as well as decreased cell growth (Fig. 1). This is consistent with our previous report of
1http://rsbweb.nih.gov/ij/
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constitutive Lyn activation in myeloid cell lines and inhibition of myeloid cell growth by Lyn
antisense (27). However, since RNA interference is not currently used as a therapeutic tool,
we further studied the efficacy of the Src kinase inhibitor dasatinib.
Src/Abl kinase inhibition
An in vitro kinase screen led to the identification of dasatinib (BMS-354825) as a potent Src/
Abl kinase inhibitor with an IC50 0.2 to 1.1 × 10−9 M and 3 × 10−9 M for SFK and Bcr-Abl
respectively. Of the nine mammalian SFK, Lyn has the greatest expression in myeloid cells
(6). A 60 minute incubation with dasatinib inhibited total SFK phosphorylation at nanomolar
concentrations in all cell lines studied, ranging from 10−9 M in Mo7e, and MV4-11 cells,
10−8 M in Ba/F3-Flt3ITD, U937, THP-1, to 10−7 M in Mo7e-KitD816H (Fig. 2A). Phospho-
Src inhibition was also investigated in the AML specimen #2956294, and was found to occur
at 10−8 M. With the exception of BcrAbl+ K562 cells as a positive control, phosphorylation
of Abl could not be detected in any of the cell lines studied (data not shown). We compared
the status of phospho-Lyn (Tyr396) and phospho-Lyn (Tyr 507) content with that of phospho-
Src (Tyr416) following dasatinib treatment, there was an approximate correlation
(Supplemental Fig. 1A). Differences in antibody characteristics (rabbit polyclonal vs. rabbit
monoclonal) may account for variance. Densitometric analysis also suggested that net Lyn
activity reflected competing effects of dasatinib-induced inhibition on Csk/Chk, which
phosphorylates the negative regulatory site at Tyr 507, and Lyn itself at its positive regulatory
site (Tyr 396) Supplemental Fig. 1B). Sensitivity analysis demonstrated that trend in net Lyn
activity was independent of antibody binding efficiency (Supplemental Fig. 1C). We found
that the 10−7 M dasatinib inhibited the tyrosine phosphorylation of Src/Abl downstream targets
CrkL and Cbl in Ba/F3-ITD and MV4-11 (Supplemental Fig. 2). Dasatinib also inhibited the
tyrosine phosphorylation of oncogenic forms of both c-Kit and Flt3 (Fig. 2B and 2C).
Phosphoproteome analysis of dasatinib-treated Mo7e cells showed two patterns. At the low
dose (10−9 M), there was inhibition of protein kinase Cδ̤ Aktı̤ anḍfocal adhesion kinase, and
at the high dose (10-5 M), ErbB2 and vascular endothelial growth factor receptor 2
(Supplemental Table 2). These data suggest that there are off-target effects of dasatinib, which
may account for the difference between the observed IC50 of dasatinib on SFK and the GI50
of various AML cell lines (see below).
Dasatinib inhibition of primary myeloid leukemia cell growth
We used two different assays to determine the effects of dasatinib on cell growth and viability:
trypan blue exclusion and MTT activity. As shown in Supplemental Table 3, dasatinib
treatment resulted in 50% growth inhibition at 3 to 6 × 10−6 M for both Flt3ITD+ and factor-
independent cell lines. The degree of growth inhibition was similar to that observed in cells
treated with a general Src kinase inhibitor PP1 (data not shown). Mo7e-KitD816H cells were
most sensitive to dasatinib (GI50 = 5 × 10−9 M). Fourteen patient samples were treated with
dasatinib or DMSO control, and viability was determined in triplicate at 48 hours. As shown
in Fig. 3A, dasatinib inhibited the growth of primary AML blasts more strongly than the
leukemic cell lines (Mann-Whitney test, P = 0.0188). The lowest GI50 at 24 hours was observed
for an AML M4 specimen that carried a gain-of-function mutation in NRAS (10−9 M). The
GI50 at 48 hours ranged between 10−9 to 1.7 × 10−6 M (Supplemental table 4). Similar values
were obtained at 72 and 96 hours (data not shown). Next, we correlated inhibition of Lyn
activation with that of growth. Viability was measured in primary myeloid leukemic cells
treated for 48 hours in the presence of varying concentrations of dasatinib. An aliquot of these
cells were also treated with dasatinib for 1 hour and analyzed for anti-phospho-Lyn (Tyr396)
content by western blotting. We identified dasatinib high sensitive and low sensitive primary
AML specimens (Fig. 3B) and observed a positive correlation in the dose-responsiveness of
dasatinib-induced Lyn inhibition and cell growth.
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Dasatinib induces G1 arrest with accumulation of p21 and p27 or apoptosis in sensitive cells
Because we observed little cytotoxicity, we hypothesized that dasatinib caused growth arrest.
Therefore, cell cycle analysis was performed on cells stained with propidium iodide and then
measured by flow cytometry. The proportion of Ba/F3-Flt3ITD, THP-1, and Mo7e cells in G1
phase increased after 24 hours of dasatinib treatment (Table 1). Exposure of THP-1 cells to
dasatinib resulted in a dose-dependent upregulation of the cyclin-dependent kinase inhibitors
p21 (Waf1) and p27 at 48 hours (Fig. 4A). At 10−5 M, we detected minor cleavage of caspase
3 but no PARP cleavage in THP-1 cells (data not shown). However, at 24 hours exposure to
dasatinib, we observed significant caspase activity, indicative of apoptosis, in cells expressing
oncogenic Kit (Fig. 4B).
Synergy with targeted and cytotoxic agents
We hypothesized that dasatinib’s effects could be synergistic with either other targeted agents
or cytotoxic drugs. In Ba/F3-FLT3ITD cells, dasatinib and rapamycin were synergistic.
Rapamycin inhibited the growth of Ba/F3-FLT3ITD cells by 14-31% when used alone at
concentrations 10−9 to 10−7 M, and the GI50 exceeded 10−6 M. The results of the combination
studies of rapamycin plus dasatinib are shown in the form of relative GI50 value, i.e. the ratio
of the GI50 of dasatinib in combination with fixed concentrations of rapamycin versus the
GI50 of dasatinib alone. The addition of rapamycin at concentrations of 10−9 and 10−8 M
decreased the GI50 of dasatinib by 25%. The addition of 10−7 M rapamycin decreased the
GI50 of dasatinib by 55% (Fig. 4C). As shown in Table 2, synergism was observed when
dasatinib is combined with cytarabine (A) or etoposide (B) at concentrations equal to their
GI50. A stronger synergy was observed at concentrations exceeding their respective GI50.
DISCUSSION
Because SFK activate many of the same growth-promoting signaling molecules associated
with Bcr-Abl, and data from our group and other investigators on the aberrant activation of
SFK, primarily Lyn, in AML cells (27-29), we studied the role of dasatinib in a variety of AML
cell lines and primary AML blasts. Src kinases, primarily Lyn, were active in all of these cell
lines and blasts cells. In our studies, phosphorylation of Src Tyr416, used to monitor an
activating autophosphorylation site, was decreased by dasatinib (30). Our preclinical studies
demonstrated that the Src-Abl inhibitor dasatinib caused growth arrest at ≤10−6 M in
molecularly heterogeneous AML cell lines and primary AML blasts. Oral dosing of dasatinib
in human clinical trials has achieved micromolar concentrations (31). Dasatinib directly
inhibits c-Kit and was highly effective in inhibiting the growth of Mo7e cells expressing an
activating mutation of Kit at 10−9 M. It is unlikely that Abl was the drug target in these cell
lines, because it was not constitutively activated (data not shown). The difference in IC50 for
SFK and GI50 suggests that a negative feedback loop exists to buffer inhibition of SFK, as has
been shown with inhibition of Akt (32). Dasatinib also inhibited Csk/Chk-mediated
phosphorylation of the Src’s autoinhibitory phosphorylation site (e.g. phospho-Src Tyr527),
which would result in an activated Src kinase (Supplemental Fig. 1A). Higher doses of dasatinib
may be required for a complete inhibition of Src kinase activity (Supplemental Fig. 1B). The
predominant Src kinase in myeloid cells, Lyn produces both stimulatory and inhibitory effects
(33), and the biologically optimal dose for growth inhibition may occur at a greater
concentration. Finally, dasatinib may have off-target effects on kinases not currently known
to play a role in AML growth. Dasatinib, however, does not inhibit the Janus, Syk, fibroblast
growth factor receptor, vascular endothelial growth factor (VEGF) receptor, or epidermal
growth factor receptor kinase activities, which have been associated with various forms of
AML cell growth (34-37). Proteomic profiling of 52 signaling proteins in primary AML blasts
reveals considerable diversity in their levels and activation states (38). We did not observe any
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dose-inhibition of phospho-ERK1/2 (a downstream effector for c-Raf) or phospho-STAT5
(data not shown).
A likely mechanism for growth inhibition without apoptosis lies in the observed cell cycle
arrest of AML cells in G1 phase. We observed a dose-dependent accumulation of the cyclin-
dependent kinase inhibitors p21 and p27. Src-activated breast cancer cell lines display reduced
p27(39). By phosphorylating Tyr88 in p27, the Src kinase Lyn promotes Cdk2-mediated
phosphorylation of Thr187, which in turn promotes its SCF-Skp2-dependent degradation.
(40). Dasatinib caused little inhibition of phospho-Erk, phospho-Akt, or phospho-STAT3 in
Mo7e-KitD816H, Ba/F3-Flt3ITD, U937, and THP-1 cells (data not shown). On the other hand,
treatment led to caspase activation in cells expressing an activating mutation of Kit. Dasatinib
may thus be effective at lower concentrations in those leukemic cells displaying Src, Abl, or
Kit oncogene addiction (41).
Our studies demonstrate that dasatinib has an anti-leukemic activity and advance its potential
use for new therapeutic approaches in AML. The optimal scheduling and combination regimen
for dasatinib in AML will be determined from clinical trials. Despite its short plasma half-life,
dasatinib was effective with a once-daily regimen in CML patients (31,42). We did not observe
greater inhibition when the drug was added daily to cell cultures (data not shown). Snead et
al have reported that dasatinib treatment of CML patient samples for 4 hours followed by
washout induced apoptosis and inhibited proliferation. Thus, continuous inhibition of kinases
may not be necessary for clinical efficacy (43). Plasma concentrations of dasatinib in patients
receiving the 70 mg twice daily or the 140 mg once daily regimens were reported to be greater
than 14.6 ng/mL (~30 nM) for 8 to 10 hours (31). These reports suggest that short exposure to
dasatinib may be sufficient, and so AML patients with low GI50 (Supplemental Table 4) might
respond to clinically achievable dose of dasatinib alone. Preliminary results from a European
phase I/II study of dasatinib in children and adolescents show that two of 12 patients with non-
mutated c-Kit, Bcr-Abl− relapsed AML responded (44). Although our results show growth
inhibition, doses required for dasatinib alone are high for the majority of patients, suggesting
that dasatinib will be most effective in combination with traditional chemotherapy agents.
Combination of dasatinib and high-dose cytarabine was effective and well tolerated in a 50
year-old man with systemic mastocytosis and AML(45). Synergistic activity of dasatinib with
rapamycin or cytotoxic agents results in an effective concentration of dasatinib achieved
through current oral dosing and provides rationale for inclusion of dasatinib in multi-drug
regimens. Given our previous findings that activation of Flt3 leads to SFK Lyn activation (9),
Src kinase inhibition may have an adjuvant role in treating leukemias harboring gain-of-
function Flt3 or Kit mutations. Therefore, there are two mechanisms whereby dasatinib may
contribute to anti-leukemia growth. In leukemic cells driven by oncogenic forms of Src, Abl,
or Kit, dasatinib may induce apoptosis. In cells that depend on Src, Abl, or Kit for salvage or
accessory growth promoting pathways, dasatinib may induce growth arrest. In the
phosphoproteome analysis of dasatinib treated cells, we observed differences in a number of
potential mediators of leukemic cell growth, including serine/threonine kinases, receptor
tyrosine kinases, and cell cycle proteins (Supplemental Table 2), Clinical trials with
combination therapy including dasatinib are warranted in AML. Future studies should identify
additional targets for dasatinib and biomarkers for sensitivity.
Translational Relevance
Acute myeloid leukemia (AML) remains one of the most difficult hematologic malignancies
to treat. Improvements in therapy will come from identification of new molecularly targeted
agents and their incorporation into multi-drug regimens. The dual Src/Abl kinase inhibitor
dasatinib has been approved for use in chronic myeloid leukemia. Dasatinib also has
efficacy against the receptor tyrosine kinase c-Kit, sometimes mutated in AML. In this
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study, we observed that dasatinib significantly inhibited growth in a variety of AML cell
lines and primary blasts. We also found that the effects of dasatinib could be enhanced with
the addition of other cytotoxic or molecular targeted agents. Our results provide rationale
for evaluating dasatinib in a multi-drug regimen for AML with a variety of molecular
lesions.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Effect of Lyn inhibition on M-o7e cells
Whole cell lysates were prepared from the mock transfected cells and cells transfected by Lyn
siRNA (100 nM) or scrambled siRNA (100 nM) after 48 hours. Western blotting confirmed
effective silencing of Lyn (insert). Effect of suppressing Lyn expression on Mo7e cell growth
was assessed at indicated time points by counting cells using the trypan blue exclusion method.
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Figure 2.
(A) Inhibition of SFK phosphorylation by dasatinib
5 ×106/ml cells were incubated for 60 minutes in growth medium with escalating doses of
dasatinib. Whole cell lysates were separated by SDS-PAGE 10% gels. 30 ug of protein was
loaded per lane. Western blotting was performed with polyclonal phospho-Src (Tyr416)
antibody with polyclonal anti-actin antibody for loading control.
(B) Inhibition of c-Kit by dasatinib (C) Inhibition of Flt3 by dasatinib
5 ×106/ml cells were incubated for 60 minutes in growth medium with escalating doses of
dasatinib. Whole cell lysates were prepared and immunoprecipitation was performed with anti-
c-Kit or anti-Flt3 antibodies at 4°C with protein A-sepharose beads. After bead complexes
were washed, samples were boiled, and resolved by SDS-PAGE 7.5% gels. 30 ug of protein
was loaded per lane. Western blotting was performed with monoclonal anti-phosphotyrosine
4G10 antibody and then reprobed for total Flt3 or c-Kit.
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Figure 3.
(A) Growth inhibition of primary AML cell by dasatinib
AML cell lines or AML specimens were treated for 48 hours with dasatinib. The growth
inhibition was assessed by trypan blue exclusion and compared to the DMSO control. GI50
were calculated using Calcusyn software. The data were plotted in PRISM and showed
significance with a Mann-Whitney test, P=0.0188.
(B) Correlation of growth inhibition and Lyn activity
AML primary cells (1×106/ml) were cultured in RPMI medium containing 20% FBS and
dasatinib (0 to 10−6 M) for 48 hours. Cell number was determined using trypan blue dye. An
aliquot of the same AML primary cells were treated with different concentrations of dasatinib
(0 to 10−6 M) for 60 min at hour 0. Cells were lysed, and 40 μg of protein lysates was
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electrophoresed and subsequently blotted with anti-phospho-Lyn (Tyr396) or anti-actin
antibodies. The western blot film was scanned and the band intensity of phospho-Lyn (Tyr396)
was quantified by densitometric analysis using ImageJ 1.42 software (National Institutes of
Health, Bethesda, MD). The scatter diagram shows the correlation between phospho-Lyn
(Tyr396) levels and cell numbers after treatment with dasatinib, delineating high sensitive and
low sensitive AML patients. Control specimens maintained viability >90 %. Positive
correlation between inhibition of Lyn activity and cell growth was observed.
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Fig. 4. Effect of dasatinib on tyrosine phosphorylation of p27 and p21 in THP-1 cells and caspase
cleavage in Mo7e-KitD816H cells
(A) Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle
distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western
blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for
48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for
comparable protein loading.
(B) Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as
detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment
with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves
as loading control.
(C) Synergy between dasatinib and rapamycin in Ba/F3-Flt3ITD: potentiation versus
inhibition analysis. Ba/F3-Flt3ITD cells were treated with dasatinib in combination with fixed
doses of rapamycin 10−7, 10−8, and 10−9 M versus dasatinib alone. Cells were collected at 48
hours, and the growth inhibition was determined by Trypan blue exclusion. Each data point
represents the average of triplicate cultures. Values of >1, 1, and <1 denote inhibition, no effect,
and potentiation, respectively.
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Table 1
Dasatinib induces growth arrest in THP-1, Ba/F3-ITD, and Mo7e cells
Cells were treated with dasatinib at the indicated concentrations for 24 hours and then stained with propidium
iodide and cell cycle distribution was analysed by flow cytometry. Percentage of cells was determined by ModFit
software.
Cell type concentration G1 S G2/M
THP-1 0 μM 47 39 14
0.1 μM 46 35 20
1 μM 50 34 17
10 μM 57 30 14
BaF3-ITD 0 μM 49 45 7
0.1 μM 50 38 12
1 μM 58 33 10
10 μM 65 23 13
Mo7e 0 μM 35 44 22
0.1 μM 34 45 22
1 μM 33 49 19
10 μM 44 49 7
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